✦ LIBER ✦

Results of treatment changes in patients with apparently drug-resistant chronic epilepsy

✍ Scribed by Anna L. Luciano; Simon D. Shorvon

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 82 KB
Volume: 62
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.21064

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained remissions and low rate of BCR

Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up

✍ Georg Hess; Ralf G. Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Chri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

Chronic myelogenous leukemia in nonlymph

Chronic myelogenous leukemia in nonlymphoid blastic phase : Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

✍ Stefano Sacchi; Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## BACKGROUND. The prognoses of patients with chronic myelogenous leukemia in blastic phase (CML-BP) are extremely poor. Treatment of patients with nonlymphoid CML-BP is associated with very low response rates, a median survival of 2-3 months, and significant toxicities. The aim of this study was

Splenic irradiation in the treatment of

Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia : Results of daily and intermittent fractionation with and without concomitant hydroxyurea

✍ Henry Wagner JR; Paul G. McKeough; Jane Desforges; Hywel Madoc-Jones 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views

The LUNDEX, a new index of drug efficacy

The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden

✍ Lars Erik Kristensen; Tore Saxne; Pierre Geborek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 1 views

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views